Certara (CERT) Q1 2026 earnings: Revenue up 1% to $106.9M; software growth at 7%, while services revenue declined. Strategic reorganization discussed.

Key Takeaways

• Total revenue for Q1 2026 was $106.9 million, up 1% year-over-year.
• Software revenue increased 7% to $49.7 million, driven by strong performance in multiple product lines.
• Services revenue declined 4% to $57.2 million, reflecting mixed results in the company's services business.
• The company expects full-year 2026 revenue guidance in the range of $395 million to $405 million, with growth of 0% to 4% year-over-year.
• A strategic reorganization was announced to focus on two distinct growth areas: Model Informed Drug Development (MID3) and Accelerated Clinical Evidence (ACE).

Financial Performance

Certara, Inc. reported its first-quarter results for 2026, revealing a mixed performance as the company navigated operational challenges while pursuing strategic initiatives. Total revenue for the quarter was $106.9 million, reflecting a 1% increase from the same period last year. However, the breakdown of revenue highlighted contrasting performances between software and services divisions.

Software revenue grew by 7%, amounting to $49.7 million—a positive indication driven by the successful launch of products like SIMSIP and Phoenix. The software bookings for the quarter also showed promise, reaching $48.7 million, which marked a 20% increase from the prior year period. On the other hand, services revenue fell by 4% to $57.2 million, primarily due to softness in the regulatory services segment and mixed results in Model Informed Drug Development services.

The net retention rate for software was reported at 106%, indicating strong customer engagement and satisfaction, which is crucial for maintaining revenue growth.

Strategic Initiatives

One of the main focal points of the earnings call was the company’s commitment to innovation and strategic partnerships. Certara emphasized its ongoing investment in AI and technology to enhance its product offerings. The company is developing an AI-integrated platform designed to unify its various software products and provide researchers with comprehensive insights derived from a vast body of data and scientific expertise.

Additionally, Certara has taken decisive steps towards streamlining its operations by announcing the divestiture of its regulatory writing and medical writing services. This move is expected to sharpen focus on areas where the company has competitive advantages, thereby enhancing predictability in revenue generation. The divestiture, which resulted in approximately $50 million in annual revenue, will allow Certara to reallocate resources toward its core software and services segments.

The company also mentioned several key partnerships, including a collaboration with NVIDIA to leverage accelerated computing and AI capabilities in its next-generation platform. This partnership is expected to reduce manual processes and enhance the efficiency of simulations, significantly benefiting clients.

Future Outlook

Looking ahead, Certara has updated its full-year guidance for 2026, anticipating revenue between $395 million and $405 million. This outlook reflects an expectation of 0% to 4% growth year-over-year, excluding the impact of the divested business. Management indicated that the first half of the year may see growth closer to the lower end of this range, while the second half is expected to improve significantly due to enhanced visibility and performance in software.

The adjusted EBITDA margin is expected to remain in the range of 30% to 32%, indicating a stable operating environment despite recent challenges. The company also projected adjusted EPS for the full year to be between $0.35 and $0.41, suggesting potential for earnings recovery as operational efficiencies improve.

Closing Thoughts

In conclusion, Certara, Inc. is navigating a complex landscape marked by mixed financial results while focusing on strategic growth initiatives. The company's decision to streamline operations and invest in AI technologies suggests a long-term commitment to enhancing its market position. While the recent decline in services revenue raises questions, the strong growth in software and proactive measures taken in response to market dynamics present a cautiously optimistic outlook for the remainder of 2026.

This analysis is based on public earnings call materials and is not investment advice.